Two investigators from the University of Colorado Cancer Center have earned a place on an international list ranking their influence in the top one percent of their respective fields. D. Ross Camidge, MD, PhD, made the Clinical Medicine list for his work in lung cancer.  Russell Glasgow, MS, PhD, was recognized in the Social Sciences category for his work in finding ways to incorporate scientific evidence into clinical practice.

The 2017 list of Highly Cited Researchers is compiled by Clarivate Analytics and recognizes researchers for their contribution and impact in science. The analysis identifies the most frequently cited researchers as determined by how often their papers have supported, influenced, inspired and challenged others in the field.

Russell Glasgow, MS, PhD

Ross Camidge, MD, chief of the Lung Cancer program at UCHealth University of Colorado Hospital

Camidge is a CU Cancer Center investigator, Joyce Zeff Chair in Lung Cancer Research and director of Thoracic Oncology at the CU School of Medicine on the Anschutz Medical Campus. Over the last decade, his work at CU has transformed the way lung cancer is managed. His contributions include developing multiple novel treatments for specific subtypes of lung cancer; describing previously unrecognized side effects of new treatments; as well as coining the term ‘oligoprogression’ to describe an early stage of progression seen with targeted approaches that is amenable to localized radiation therapy to prolong disease control. Most recently, he was instrumental in crafting new international guidelines for more appropriately addressing patients whose cancer has spread to the brain or central nervous system within clinical trials.

“While no one wants to get lung cancer, it is better to get it now than even a few years ago. Everyone – patients, researchers and medical providers – have benefited from recent clinical breakthroughs,” says Camidge.

He notes that some people with advanced lung cancer can now live for years, something unheard of a decade ago. “Some of that progress has come from new drugs, but some of it comes from learning each drug’s optimal use and being more creative about how we use even well established treatments.”

“The fact that our scientific and medical team here has contributed to the field and CU’s work is recognized as having influenced others is fantastic. It keeps us all going,” says Camidge. “I can’t wait to see what the next ten years bring.”

Glasgow’s research involves looking for creative ways to incorporate scientific findings into clinical practice. Has contributed major models, measures and intervention evaluations in cancer and other chronic illnesses.

The methodology that determines the who’s who of researchers draws on the data and analysis performed by bibliometric experts from Clarivate Analytics.  It uses Essential Science Indicators, 2005-2015, a compilation of science performance metrics and trend data based on scholarly paper publication counts and citation data from the Web of Science, the premier web-based environment of scientific and scholarly research literature totaling over 33,000 journals.